Mymetics Corporation (OTCQB: MYMX) is a Swiss-based biotechnology company registered in the US and trades on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies.

Mymetics develops next-generation preventative vaccines for infectious diseases. Mymetics’ core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. The company’s vaccines are designed to induce protection against early transmission and infection, focusing on the mucosal immune response as a first-line defense, which, for some pathogens, may be essential for the development of an effective prophylactic vaccine.

Mymetics currently has 5 vaccines in its pipeline: HIV-1/AIDS, intra nasal Influenza, Malaria, Herpes Simplex Virus and the RSV vaccine (out licensed to ClearPath – Astellas). The company’s intra nasal Influenza vaccine and the HIV-1 vaccine have successfully completed Phase I clinical trials in healthy human volunteers. A Phase 1b clinical trial for its Malaria vaccine on children in Tanzania has been completed, while the HSV vaccine candidate is in the preclinical phase.
Domain: Therapeutics & Diagnostics, Vaccines
Contact: Rte de la Corniche 4
1066 Epalinges / VD
P: 021 653 45 35
F: 021 653 24 73

http://www.mymetics.com
Find an actor

Journée de l'Innovation 2017 aux HUG Jeudi 19 octobre19.10.2017

11ème Journée de l’innovation au Centre de l’innovation des HUG. Conférences, concours de pitchs, remise des...

Pryv SA closes 1.1M CHF Pre-Series A to accelerate growth and prepare Series A funding round

Pryv SA, an independent Swiss Health-IT company, specialized in providing innovative data management and digital...
Print this page Download this page (PDF) Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

Find us on LinkedIn